Abbott Cuts 2026 Sales Outlook and Moves to Spin Off Nutrition Unit
Abbott Laboratories lowered its 2026 sales growth outlook and said it will separate its nutrition business into an independent company, marking a major strategic reset for one of the world’s largest healthcare conglomerates. The move comes as the company seeks to sharpen its portfolio after years of scrutiny over its infant formula operations and as investors reassess the growth profile of the broader business.
